WHITE PAPER
IQVIA Pharma Deals Review of 2021
IQVIA Pharma Deals
Mar 15, 2022

The IQVIA Pharma Review of 2021 provides an insightful overview of deal activity in 2021, as well as an outlook for 2022. Key information provided includes the following:

  • Top M&A and partnership deals in 2021
  • Deal activity rankings of the top pharmaceutical companies
  • Deal activity by therapeutic area and development phase
  • Deal value analysis of M&A, licensing and R&D deals

Key Highlights:

  • Deal activity in the life sciences sector was reinvigorated in 2021, jumping above pre-pandemic levels as big players sought new growth drivers and rapid advances in scientific and technological innovation drove collaboration.
  • M&A activity rebounded both in terms of volume and deal value in 2021 despite mega deals being conspicuously absent in the pharmaceutical sector as cautious companies instead favored bolt-on acquisitions. However, the exceptional level of collaborative R&D activity that was elicited in response to COVID-19 could not be sustained in 2021.
Contact Us